Tweets
ACR22: Polymyalgia Rheumatica in the Spotlight
One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will be the emphasis on PMR. Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run.
https://t.co/SYKT3a03Tc https://t.co/9CIRp66vSK
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Estimated Global SLE market size was $1.46 billion in 2020, with a global (7 Major countries) prevalence of 651,965 in 2020; and a USA prevalence of 351,176 SLE cases. https://t.co/f4Tghup5PC https://t.co/p1w9KFQR4z
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
1602 pemphigus pts Rx w/ rituximab vs azathioprine or MMF. RTX pts had lower risk of MI (RR 0.45; P = .01), CVA (RR, 0.42; P < .001), PVD (0.47), HTN (0.48), hyperlipidemia (0.45), NIDDM (0.63), obesity (0.49). Mortality equal betw groups https://t.co/uvDDU5z8gp https://t.co/kJAg5xRKHz
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/GQEp8N0uZb https://t.co/TxfyIemzBT
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
NRMP Results for rheumatology 2022 :
- Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied)
- Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29 applied)
WE NEED MORE ADULT PROGRAMS AND MORE INTEREST IN PEDI RHEUM https://t.co/YpMhTPnDM4 https://t.co/Aa3EV57yij
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
AURORA1 RCT
📍Efficacy of voclosporin in LN III-V with UPC > 1.5g
💊VOC 23.7 mg BID vs. PCB
💊All got MMF 1g BID and GC
🥇#1 outcome: UPC < 0.5, stable 🫘 fx, ❌ GC > 10 mg
-40% VOC v. 23% PCB (sig)
-all measures favored VOC, but only sig. for UPC < 0.5
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 7 months ago
Topic Podcasts - JAK TYK2
https://t.co/DqfEj955aw https://t.co/HRj28berzF
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
A great read from Dr. Anthony Fauci as he steps down from leading the NIH NIAID research for nearly 40 years. He writes on pundits, need for specialty growth, evolution of vaccines and "it aint over till its over" is now "its never over" https://t.co/z0noGckIvx https://t.co/DJKG88V1mc
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Estimated worldwide market for DMARDs in 2022 was $20.7 billion USD and is expected to rise at a 3.5% annual growth rate to $ 272 billion USD by 2030 https://t.co/futp7249rF https://t.co/QgxJR7TQNw
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope ( @Janetbirdope) and Dr. Jonathan Kay ( @RheumKay) discuss the Great Debate, which Dr. Pope participated in, at #ACR22.
https://t.co/PPXiX8MG6m https://t.co/Uy0kQd7XGz
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Fertility issues in SpA
Dr. Sheila Reyes ( @RHEUMarampa) speaks with Dr. Sabrina Hamroun about abstract 1673 at #ACR22.
https://t.co/SvCuE4fx04 https://t.co/DAveKT29J8
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
Does Race play a role in Mycophenolate Response in Scleroderma
Dr. Eric Dein ( @ericdeinmd) speaks with Dr. Lauren Smith about abstract 0521 at #ACR22.
https://t.co/3lcVjfMsub https://t.co/P3XcsiXgWa
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 7 months ago
